Dr. Wendy C. Moore, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 83
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of Maryland School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 2000 00556 -
Critical Care Medicine (Internal Medicine) Physician
NC license 2000 00556
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Carolina Baptist Hospital Winston-Salem, NC
Medical groups
- Wake Forest University Health Sciences (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 83
- Services billed
- 10,617
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, mepolizumab, 1 mg | 3,800 | 11 |
| Injection of drug or substance under skin or into muscle | 71 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 42 |
| Established patient office or other outpatient visit, 40-54 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Winston Salem, NC | 169 |
| Azithromycin Other prescribers in Winston Salem, NC | 160 |
| Montelukast Sodium Other prescribers in Winston Salem, NC | 138 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Winston Salem, NC | 123 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Winston Salem, NC | 102 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Winston Salem, NC | 92 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Winston Salem, NC | 79 |
| Nucala (mepolizumab) | 73 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Winston Salem, NC | 68 |
| Tezspire (tezepelumab-ekko) | 64 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $283 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $283 |
|---|
| Travel and Lodging | $186 |
|---|---|
| Food and Beverage | $97.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Feb 21, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $115 |
| AstraZeneca Pharmaceuticals LP Feb 21, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $70.67 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 5 companies. The companies reported $213,370 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, parallel group, multi-center study to eval
GlaxoSmithKline, LLC. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - A prospective, real-world, interventional study to evaluate the effect
GlaxoSmithKline, LLC. - A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose…
AstraZeneca Pharmaceuticals LP - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.